ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 – 6 inclusive) were duly passed by shareholders. Details are contained in the table below.
| Resolution | For | % For | Against | % Against | Withheld |
| 1. To receive the accounts of the Company for the year ended 31 December 2025 together with the reports thereon of the directors and auditors of the Company | 163,496,678 | 99 | 2,252,180 | 1 | 365,965 |
| 2. To re-appoint Ketan Patel as a director of the Company | 156,211,793 | 98 | 3,080,916 | 2 | 6,822,114 |
| 3. To re-appoint Crowe UK LLP as Auditor of the Company | 163,482,368 | 99 | 2,311,240 | 1 | 321,215 |
| 4. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the “Act”) to allot shares on the basis as set out in the Notice of Meetin | 152,641,450 | 94 | 11,960,794 | 6 | 1,512,579 |
| SPECIAL RESOLUTION
5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the “Act”) to allot shares on the basis as set out in the Notice of Meeting |
151,322,867 | 93 | 13,507,185 | 7 | 1,284,771 |
| SPECIAL RESOLUTION
6. That, with effect from the conclusion of the Annual General Meeting, the draft Articles of Association be adopted as the Articles of Association of the Company in substitution for, and to the exclusion of, the Company’s existing Articles of Association |
155,666,377 | 96 | 7,767,242 | 4 | 2,681,204 |
To download announcement click here